Drug patents …
… from Kazakhstan to Kalamazoo
Find generic entry opportunities
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Anticipate generic drug launch
Manage your formulary budget
Proactively manage your pharmacy inventory
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Terazosin polymorph and pharmaceutical composition|
|Abstract:||A novel anhydrous crystalline polymorph of 1-(4-amino-6,7-dimethoxy- 2-quinazolinyl)-4-(2-tetrahydrofuroyl)piperazine monohydrochloride is disclosed, together with pharmaceutical formulations containing the compound. The novel polymorph exhibits a diminished food effect when administered to human subjects.|
|Inventor(s):||Meyer; Glenn A. (Waukegan, IL), Bauer; John F. (Lake Bluff, IL)|
|Assignee:||Abbott Laboratories (Abbott Park, IL)|
Patent Claim Types:|
see list of patent claims
|Compound; Composition; Dosage form; Use;|
|Patent Number||Expiration Date|
|5,294,615||March 15, 2006|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|Austria||130853||<disabled in preview>|
|Austria||182592||<disabled in preview>|
|Canada||2107382||<disabled in preview>|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.